• Vaccine Name: NYVAC- CDV-H/F
• Target Pathogen: Canine distemper virus
• Target Disease: Canine distemper
• Vaccine Ontology ID: VO_0004772
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• CDVgp6 haemagglutinin protein H gene engineering:
  • Type: Recombinant vector construction
  • Description: Attenuated vaccinia virus (NYVAC) or canarypox virus (ALVAC) vaccine strains expressing the CDV hemagglutinin (H) and fusion (F) protein genes (NYVAC-HF and ALVAC-HF) (Welter et al., 2000).
  • Detailed Gene Information: Click Here.
• CDVgp5 gene engineering:
  • Type: Recombinant vector construction
  • Description: Attenuated vaccinia virus (NYVAC) or canarypox virus (ALVAC) vaccine strains expressing the CDV hemagglutinin (H) and fusion (F) protein genes (NYVAC-HF and ALVAC-HF) (Welter et al., 2000).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001093
• Preparation: An attenuated vaccinia virus (NYVAC) vaccine strain expressing the CDV hemagglutinin (H) and fusion (F) protein genes (NYVAC-HF) (Welter et al., 2000).
• Immunization Route: Intramuscular injection (i.m.)

Ferret Response

• Vaccination Protocol: Ferrets without maternal antibody were vaccinated intranasally with NYVAC-HF and ALVAC-HF. While ferrets with maternal antibody were vaccinated parenterally with NYVAC-HF and ALVAC-HF (Welter et al., 2000).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: At 12 weeks of age, the ferrets were challenged with CDV (Welter et al., 2000).
• Efficacy: Both the NYVAC and attenuated CDV vaccines protected against the development of some clinical signs of infection. The results suggest that infant ferrets are less responsive to i.n. vaccination (Welter et al., 2000).